ResApp Health Limited has entered into a three-year distribution agreement with Sanrai International. Sanrai will distribute ResAppDx through its network of offices and distributors covering emerging markets. Sanrai will be a preferred distributor in the majority of these countries, except in major markets such as India, Mexico and Brazil. ResAppDx uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's built-in microphone. It is CE Marked in Europe and TGA approved for ARTG listing in Australia. ResApp will work with Sanrai to obtain regulatory approvals in additional countries, where required. It is anticipated that the majority of the use will be in- clinic.